Empagliflozin (empagliflozin)

Empagliflozin (SGLT2 inhibitor (sodium-glucose co-transporter 2 inhibitor), originally Jardiance (欧唐静 in China / Chinese-language SEA markets); Jardiance Duo for the metformin combination by Boehringer Ingelheim, co-marketed with Eli Lilly and Company (licensed from Boehringer Ingelheim International GmbH)) Empagliflozin blocks the SGLT2 protein in the kidney so that less glucose is reabsorbed and more leaves the body in the urine. Blood sugar falls without extra insulin, and the extra salt and water loss lowers the workload on the heart and protects the kidneys. The same effect is why it helps people with heart failure or chronic kidney disease even if they do not have diabetes. 10 mg orally once daily in the morning, with or without food, for all indications. For additional glycemic control the dose may be increased to 25 mg once daily in patients who tolerate 10 mg. Heart failure and chronic kidney disease are treated with 10 mg once daily.

Standard dosing for empagliflozin: 10 mg orally once daily in the morning, with or without food, for all indications. For additional glycemic control the dose may be increased to 25 mg once daily in patients who tolerate 10 mg. Heart failure and chronic kidney disease are treated with 10 mg once daily. Dose adjustments: Assess renal function before initiation and as clinically indicated, and correct volume depletion before starting. Use for glycemic control is not recommended if eGFR is less than 30 mL/min/1.73 m2. Data are insufficient for a dosing recommendation in type 2 diabetes with established cardiovascular disease and eGFR less than 30, or in heart failure with eGFR less than 20. Not for use in patients on dialysis. No dose adjustment based on age, but patients 75 years and older have a higher risk of volume depletion and reduced efficacy. No dose adjustment for hepatic impairment in the US label. Withhold for at least 3 days, if possible, before surgery or procedures involving prolonged fasting.

Empagliflozin is approved for: To reduce the risk of cardiovascular death and hospitalization for heart failure in adults with heart failure (US 2025 label); To reduce the risk of sustained decline in eGFR, end-stage kidney disease, cardiovascular death, and hospitalization in adults with chronic kidney disease at risk of progression; To reduce the risk of cardiovascular death in adults with type 2 diabetes mellitus and established cardiovascular disease; As an adjunct to diet and exercise to improve glycemic control in adults and pediatric patients aged 10 years and older with type 2 diabetes mellitus; In the EU (EMPEROR programme), the heart failure indication covers adults with symptomatic chronic heart failure across the full ejection fraction range. It is a empagliflozin (SGLT2 inhibitor), originally marketed as Jardiance (欧唐静 in China / Chinese-language SEA markets); Jardiance Duo for the metformin combination by Boehringer Ingelheim, co-marketed with Eli Lilly and Company (licensed from Boehringer Ingelheim International GmbH).

Bangladesh benchmark: 35 manufacturers sell generic empagliflozin 10 mg; unit prices range from BDT 12 (US$0.10) to BDT 30 (US$0.24), i.e. about US$2.93–US$7.32 per 30 units. Cheapest listed brand: Epaglin (Army Pharma Limited) at BDT 12 per unit. Originator comparison: Jardiance (Radiant Pharmaceuticals Ltd. (Mfg. by: Boehringer Ingelheim)) is listed at BDT 69 per unit — roughly 475% more than the cheapest generic. Prices move with pack size, pharmacy and the exchange rate — confirm current stock and price with a licensed importer before ordering.

Empagliflozin (SGLT2 inhibitor (sodium-glucose co-transporter 2 inhibitor), originally Jardiance (欧唐静 in China / Chinese-language SEA markets); Jardiance Duo for the metformin combination by Boehringer Ingelheim, co-marketed with Eli Lilly and Company (licensed from Boehringer Ingelheim International GmbH)) Empagliflozin blocks the SGLT2 protein in the kidney so that less glucose is reabsorbed and more leaves the body in the urine. Blood sugar falls without extra insulin, and the extra salt and water loss lowers the workload on the heart and protects the kidneys. The same effect is why it helps people with heart failure or chronic kidney disease even if they do not have diabetes. 10 mg orally once daily in the morning, with or without food, for all indications. For additional glycemic control the dose may be increased to 25 mg once daily in patients who tolerate 10 mg. Heart failure and chronic kidney disease are treated with 10 mg once daily.

Empagliflozin (SGLT2 inhibitor (sodium-glucose co-transporter 2 inhibitor), originally Jardiance (欧唐静 in China / Chinese-language SEA markets); Jardiance Duo for the metformin combination by Boehringer Ingelheim, co-marketed with Eli Lilly and Company (licensed from Boehringer Ingelheim International GmbH)) Empagliflozin blocks the SGLT2 protein in the kidney so that less glucose is reabsorbed and more leaves the body in the urine. Blood sugar falls without extra insulin, and the extra salt and water loss lowers the workload on the heart and protects the kidneys. The same effect is why it helps people with heart failure or chronic kidney disease even if they do not have diabetes. 10 mg orally once daily in the morning, with or without food, for all indications. For additional glycemic control the dose may be increased to 25 mg once daily in patients who tolerate 10 mg. Heart failure and chronic kidney disease are treated with 10 mg once daily.

Empagliflozin (SGLT2 inhibitor (sodium-glucose co-transporter 2 inhibitor), originally Jardiance (欧唐静 in China / Chinese-language SEA markets); Jardiance Duo for the metformin combination by Boehringer Ingelheim, co-marketed with Eli Lilly and Company (licensed from Boehringer Ingelheim International GmbH)) Empagliflozin blocks the SGLT2 protein in the kidney so that less glucose is reabsorbed and more leaves the body in the urine. Blood sugar falls without extra insulin, and the extra salt and water loss lowers the workload on the heart and protects the kidneys. The same effect is why it helps people with heart failure or chronic kidney disease even if they do not have diabetes. 10 mg orally once daily in the morning, with or without food, for all indications. For additional glycemic control the dose may be increased to 25 mg once daily in patients who tolerate 10 mg. Heart failure and chronic kidney disease are treated with 10 mg once daily.

Jardiance is the innovator and reference product (10 mg and 25 mg film-coated tablets); empagliflozin itself is off patent in many markets and local manufacturers are expected to show bioequivalence of the same strengths. As of the sources reviewed, the US market had no FDA-approved generic empagliflozin, so US-sourced generic claims should be treated with caution; Indian and Bangladeshi copies are locally approved rather than FDA/EMA approved. Confirm the specific brand against the local regulator's registered-products list before making equivalence claims. Manufacturers supplying empagliflozin generic versions include Beacon Pharmaceuticals PLC, Beximco Pharmaceuticals Ltd., Cipla Ltd., Eskayef Pharmaceuticals Ltd., Incepta Pharmaceuticals Ltd., Lupin Ltd., Natco Pharma, Renata PLC. Brands registered in Bangladesh include Adempa, Ajardy, Ardance, Coport, D-Fozin, Diampa.

Empagliflozin (SGLT2 inhibitor (sodium-glucose co-transporter 2 inhibitor), originally Jardiance (欧唐静 in China / Chinese-language SEA markets); Jardiance Duo for the metformin combination by Boehringer Ingelheim, co-marketed with Eli Lilly and Company (licensed from Boehringer Ingelheim International GmbH)) Empagliflozin blocks the SGLT2 protein in the kidney so that less glucose is reabsorbed and more leaves the body in the urine. Blood sugar falls without extra insulin, and the extra salt and water loss lowers the workload on the heart and protects the kidneys. The same effect is why it helps people with heart failure or chronic kidney disease even if they do not have diabetes. 10 mg orally once daily in the morning, with or without food, for all indications. For additional glycemic control the dose may be increased to 25 mg once daily in patients who tolerate 10 mg. Heart failure and chronic kidney disease are treated with 10 mg once daily.

Empagliflozin (SGLT2 inhibitor (sodium-glucose co-transporter 2 inhibitor), originally Jardiance (欧唐静 in China / Chinese-language SEA markets); Jardiance Duo for the metformin combination by Boehringer Ingelheim, co-marketed with Eli Lilly and Company (licensed from Boehringer Ingelheim International GmbH)) Empagliflozin blocks the SGLT2 protein in the kidney so that less glucose is reabsorbed and more leaves the body in the urine. Blood sugar falls without extra insulin, and the extra salt and water loss lowers the workload on the heart and protects the kidneys. The same effect is why it helps people with heart failure or chronic kidney disease even if they do not have diabetes. 10 mg orally once daily in the morning, with or without food, for all indications. For additional glycemic control the dose may be increased to 25 mg once daily in patients who tolerate 10 mg. Heart failure and chronic kidney disease are treated with 10 mg once daily.